Citations
Mayo Clinic
2095 citation(s) found for "Xu, Vincent".
Utility of restaging bone marrow biopsy (BMB) in PET-negative patients with diffuse large B-cell lymphoma (DLBCL) with bone marrow involvement.
Jackson, Amie E., Smeltzer, Jacob P., Jones, Jason M. , Burnette, Brian L., Ristow, Kay M., Wiseman, Gregory A., Macon, William R. , Nowakowski, Grzegorz S. , Habermann, Thomas M. , Witzig, Thomas E.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8541-8541
SWOG 1211: A randomized phase I/II study of optimal induction therapy for newly diagnosed high-risk multiple myeloma (HRMM).
Usmani, Saad Zafar, Hoering, Antje , Sexton, Rachel , Shah, Jatin J., Fredette, Sandi, Durie, Brian G.M. , Zonder, Jeffrey A. , Dhodapkar, Madhav V. , Mahindra, Anuj, Zimmerman, Todd M., Richardson, Paul G. , Usmani, Saad Zafar, Ailawadhi, Sikander , Rajkumar, S. Vincent , Richardson, Paul Gerard Guy , Orlowski, Robert Z.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS8624-TPS8624
E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma (MM).
Stewart, A. Keith, Jacobus, Susanna , Weiss, Matthias , Chanan‐Khan, Asher , Fonseca, Rafaël , Callander, Natalie S. , Rajkumar, S. Vincent
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8511-8511
A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial.
Konecny, Gottfried E. , Jänicke, F., Beckmann, Matthias W. , Feisel, Gabriele, Pölcher, Martin , Rody, Achim , Ray-Coquard, Isabelle Laure, Provencher, Diane , Ben‐Baruch, Noa, Cottu, Paul , Chen, Hsiao‐Wang, Dering, Judy, Jacod, Sylvie, Houé, Vincent, Slamon, Dennis J. , Haluska, Paul , Sehouli, Jalid , Roman, Lynda D. , Karlan, Beth Y. , Wang, Chen
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 5529-5529
Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
Kefford, Richard , Hamid, Omid , Hodi, F. Stephen , Gangadhar, Tara C., Dronca, Roxana , Patnaik, Amita , Zarour, Hassane M. , Dolled‐Filhart, Marisa, Lunceford, Jared , Emancipator, Kenneth , Ebbinghaus, Scot, Kang, Soonmo Peter, Hwu, Wen‐Jen , Ribas, Antoni , Robert, Caroline , Daud, Adil , Wolchok, Jedd D. , Joshua, Anthony M. , Hersey, Peter , Weber, Jeffrey S.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3005-3005
A phase 1 study of a novel inhibitor of protein phosphatase 2A alone and with docetaxel.
John, Kovach, Chung, Vincent , Mansfield, Aaron S.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS2636-TPS2636
ECOG multiple myeloma (MM) clinical trial (CT) accrual performance evaluation utilizing the NCITrial Complexity and Elements Scoring (NCI-TCES) and the NCI Myeloma Steering Committee Accrual Working Group (NCI MYSC AWG) scoring models.
Weiss, Matthias , Jacobus, Susanna , Munshi, Nikhil C. , Kumar, Shaji , Lacy, Martha Q. , Stewart, A. Keith, Friedenberg, William R., Kyle, Robert A. , Greipp, Philip R., Gertz, Morie A. , Lonial, Sagar , Fonseca, Rafaël , Dispenzieri, Angela , Rajkumar, S. Vincent
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8600-8600
Free light chain assay and cytogenetic abnormalities for identification of high-risk smoldering myeloma.
Larsen, Jeremy T. , Kumar, Shaji , Esplin, Brandt L., Morice, William G. , Kyle, Robert A. , Gonsalves, Wilson I. , Gupta, Vinay Kumar , Ketterling, Rhett P. , Morice, William George , Dispenzieri, Angela , Rajkumar, S. Vincent
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8595-8595
Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma.
Ali, Siraj M. , He, Jie , Chmielecki, Juliann , Pinder, Mary , Akerley, Wallace , Wang, Kai , Molina, Julian R. , Yelensky, Roman , Palmer, Gary A. , Morosini, Deborah, Lipson, Doron , Stephens, Phil , Salgia, Ravi , Miller, Vincent A. , Ou, Sai‐Hong Ignatius , Peled, Nir , Pinder, Mary Colleen, Palma, Norma Alonzo , Ross, Jeffrey S , Frampton, Garrett M. , Bazhenova, Lyudmila
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8049-8049
Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.
Elassaiss‐Schaap, Jeroen , Hodi, F. Stephen , Hamid, Omid , Hwu, Wen‐Jen , Kefford, Richard , Patnaik, Amita , Alwis, Dinesh P. de, Perrone, Andrea , Kang, Soonmo Peter, Ebbinghaus, Scot, Anderson, Keaven M. , Gangadhar, Tara C., Joseph, Richard W. , Wolchok, Jedd D. , Joshua, Anthony M. , Ribas, Antoni , Robert, Caroline , Daud, Adil , Hersey, Peter , Weber, Jeffrey S. , Perrone, Andrea Marie
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3015-3015